Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Dietrich Alexander Ruess(University Medical Center Freiburg), Guus J.J.E. Heynen(Max Delbrück Center), Katrin J. Ciecielski(TUM Klinikum), Jiaoyu Ai(TUM Klinikum), Alexandra Berninger(TUM Klinikum), Derya Kabacaoğlu(TUM Klinikum), Kıvanç Görgülü(TUM Klinikum), Zahra Dantes(TUM Klinikum), Sonja M. Wörmann(TUM Klinikum), Kalliope N. Diakopoulos(TUM Klinikum), Angeliki F. Karpathaki(TUM Klinikum), Marlena Kowalska(TUM Klinikum), Ezgi Kaya-Aksoy(TUM Klinikum), Liang Song(TUM Klinikum), Eveline A. Zeeuw van der Laan(Max Delbrück Center), María P. López‐Alberca(Leibniz-Forschungsinstitut für Molekulare Pharmakologie), Marc Nazaré(Leibniz-Forschungsinstitut für Molekulare Pharmakologie), Maximilian Reichert(TUM Klinikum), Dieter Saur(TUM Klinikum), Mert Erkan(Koç University), Ulrich T. Hopt(University of Freiburg), Bruno Sáinz(Instituto de Investigaciones Biomédicas Sols-Morreale), Walter Birchmeier(Max Delbrück Center), Roland M. Schmid(TUM Klinikum), Marina Lesina(TUM Klinikum), Hana Algül(TUM Klinikum)
Nature Medicine
May 24, 2018
Cited by 369

Abstract


Related Papers

No related papers found

Powered by citation graph analysis